Is glucose-6-phosphatase dehydrogenase deficiency associated with severe outcomes in hospitalized COVID-19 patients?

Abstract Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is known to suppress the antioxidant system and likely aggravate severity of COVID-19, which results in a pro-oxidant response. This possible association has not been explored adequately human studies. In this research, we report that occurrence non-invasive ventilation, intubation or death—all are indicative severe significantly different hospitalized COVID-19 patients with without G6PDd (4.6 vs. 6.4%, p = 0.33). The likelihood developing any these outcomes were slightly lower after accounting for age, nationality, presence comorbidities drug interventions (Odds ratio 0.40, 95% confidence intervals 0.142, 1.148). Further investigation extends both, non-hospitalized patients, warranted study potential association.